Caveolin 1 Rabbit anti-Canine, Hamster, Human, Mouse, Rat, Polyclonal, Invitrogen
Rabbit Polyclonal Antibody
Manufacturer: Invitrogen PA1064
PA1-064 detects caveolin 1 from human, canine, hamster, mouse, and rat tissues and cells. PA1-064 has been successfully used in Western blot and immunoprecipitation procedures. By Western blot, this antibody detects an ~22 kDa protein representing caveolin 1 from rat heart protein extract. The PA1-064 immunogen is a synthetic peptide corresponding to residues M(1) S G G K Y V D S E G H L Y T V P(17) C of human CAV1. This sequence is completely conserved between human, mouse, canine, bovine, and rat. The PA1-064 immunizing peptide (Cat. No. PEP-146) is available for use in neutralization and control experiments.Caveolin-1 or CAV1 is a scaffolding proteins within caveolar membranes. It interacts directly with G-protein alpha subunits and can functionally regulate their activity. Caveolin-1 is also involved in the co-stimulatory signal essential for T-cell receptor (TCR) mediated T-cell activation. It can bind with DPP4 and induces T-cell proliferation and NF-kappa-B activation in a T-cell receptor/CD3-dependent manner. Mutations affecting the CAV1 gene can result in congenital generalized lipodystrophy 3, pulmonary hypertension primary 3, or partial lipodystrophy/congenital cataracts, and neurodegeneration syndrome.
|Synthetic peptide corresponding to residues M(1) S G G K Y V D S E G H L Y T V P(17) C of human CAV1.|
|Antigen affinity chromatography|
|Canine, Hamster, Human, Mouse, Rat|
|Immunocytochemistry, Immunofluorescence, Immunoprecipitation, Western Blot|
|PBS with 1mg/mL BSA and 0.05% sodium azide|
|P33724, Q03135, P49817, P41350|
|-20° C, Avoid Freeze/Thaw Cycles|
|100753021, 12389, 25404, 403980, 857|
We continue to work to improve your shopping experience and your feedback regarding this content is very important to us. Please use the form below to provide feedback related to the content on this product.
Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.Ok